Rizvi Ali A, Stoian Anca Pantea, Janez Andrej, Rizzo Manfredi
Department of Medicine, University of Central Florida College of Medicine, Orlando, FL 32827, USA.
Division of Endocrinology, Diabetes and Metabolism University of South Carolina School of Medicine Columbia, Columbia, SC 29209, USA.
Biomedicines. 2021 Oct 29;9(11):1579. doi: 10.3390/biomedicines9111579.
Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atherosclerosis and cardiovascular events. In addition to the traditionally available lipid-lowering treatment options, certain novel therapies have been shown to favorably impact sdLDL, among them the antidiabetic class of agents known as glucagon-like peptide 1 receptor agonists (GLP1-RAs). These drugs seem to alter the pathophysiologic mechanisms responsible for the formation and accumulation of atherogenic lipoprotein particles, thus potentially reducing cardiovascular outcomes. They represent a uniquely targeted therapeutic approach to reduce cardiometabolic risk and warrant further study for their beneficial nonglycemic actions.
血脂异常是心血管疾病（CVD）发生和进展的一个重要危险因素，低密度脂蛋白（LDL）的浓度和类型均增强了这种关联。小而密的LDL（sdLDL）亚组分是对动脉粥样硬化和心血管事件预测性最强的亚型。除了传统的降脂治疗选择外，某些新型疗法已被证明对sdLDL有有利影响，其中包括一类名为胰高血糖素样肽1受体激动剂（GLP1-RAs）的抗糖尿病药物。这些药物似乎改变了导致致动脉粥样硬化脂蛋白颗粒形成和积累的病理生理机制，从而有可能降低心血管疾病结局。它们代表了一种独特的靶向治疗方法，可降低心脏代谢风险，其有益的非血糖作用值得进一步研究。
